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Orange juice–derived flavanone and phenolic metabolites do not
acutely affect cardiovascular risk biomarkers: a randomized,
placebo-controlled, crossover trial in men at moderate risk of
cardiovascular disease1–5
Manuel Y Sch€ar, Peter J Curtis, Sara Hazim, Luisa M Ostertag, Colin D Kay, John F Potter, and Aedín Cassidy
ABSTRACT
Background: Epidemiologic data suggest inverse associations
between citrus flavanone intake and cardiovascular disease
(CVD) risk. However, insufficient randomized controlled trial data
limit our understanding of the mechanisms by which flava-
nones and their metabolites potentially reduce cardiovascular risk
factors.
Objective: We examined the effects of orange juice or a dose-
matched hesperidin supplement on plasma concentrations of es-
tablished and novel flavanone metabolites and their effects on
cardiovascular risk biomarkers in men at moderate CVD risk.
Design: In an acute, randomized, placebo-controlled crossover trial,
16 fasted participants (aged 51–69 y) received orange juice or a hes-
peridin supplement (both providing 320 mg hesperidin) or control
(all matched for sugar and vitamin C content). At baseline and 5 h
postintake, endothelial function (primary outcome), blood pressure,
arterial stiffness, cardiac autonomic function, platelet activation,
and NADPH oxidase gene expression and plasma flavanone metab-
olites were assessed. Before each intervention, a diet low in flavo-
noids, nitrate/nitrite, alcohol, and caffeine was followed, and a
standardized low-flavonoid evening meal was consumed.
Results: Orange juice intake significantly elevated mean 6 SEM
plasma concentrations of 8 flavanone (1.75 6 0.35 mmol/L, P ,
0.0001) and 15 phenolic (13.27 6 2.22 mmol/L, P , 0.0001) me-
tabolites compared with control at 5 h postconsumption. Despite
increased plasma flavanone and phenolic metabolite concentrations,
cardiovascular risk biomarkers were unaltered. After hesperidin
supplement intake, flavanone metabolites were not different from
the control, suggesting altered absorption/metabolism compared
with the orange juice matrix.
Conclusions: After single-dose flavanone intake within orange
juice, circulating flavanone and phenolic metabolites collectively
reached a concentration of 15.20 6 2.15 mmol/L, but no effects
were observed on CV risk biomarkers. Longer-duration random-
ized controlled trials are required to examine previous associa-
tions between higher flavanone intakes and improved
cardiovascular health and to ascertain the relative importance of
food matrix and flavanone-derived phenolic metabolites. This trial
was registered at clinicaltrials.gov as NCT01530893. Am J
Clin Nutr doi: 10.3945/ajcn.114.104364.
Keywords: flavonoids, flavanones, phenolic metabolites, random-
ized controlled trial, vascular function
INTRODUCTION
Cardiovascular disease (CVD) is a major cause of mortality
worldwide, accounting for 32% of deaths in the United States and
United Kingdom, with men being at a higher risk than women (1,
2). Recent data suggest that diets rich in fruit were the third most
important modifiable factor for reducing global CVD-related
morbidity and mortality, with only blood pressure–lowering
medication and smoking cessation having greater effects (3).
As citrus fruit is consumed widely, the cardiovascular protective
effects of fruit per se may in part be related to citrus fruit intake
and specifically to their flavanone (a flavonoid subclass) and
vitamin C content (4). In support of this, epidemiologic data
provide evidence to suggest that flavanones and intake of citrus
fruit are inversely associated with CVD mortality (5–7). In ad-
dition, animal and in vitro studies have reported that flavanones
improve endothelial function [principally via enhanced pro-
duction or reduced NADPH oxidase-dependent elimination of
endothelial nitric oxide (8, 9)] and cardiac autonomic function (10),
as well as reduce blood pressure (11) and platelet reactivity (12).
However, there remain insufficient data from human randomized
controlled trials to determine the relative bioactivity of dietary fla-
vanones and their metabolites. Moreover, acute and chronic studies
are needed to establish the relative effects of the different bioactive
constituents, particularly the flavanones and vitamin C.
In the limited number of previously published randomized
controlled trials, improvements in endothelial function or
a reduction in diastolic blood pressure have been observed
after short-chronic intake (3- or 4-wk duration) of a flavanone
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supplement and/or orange juice (9, 13). However, few studies to
date have established acute responses to flavanones, and thus the
potential mechanisms for a cardiovascular benefit remain unclear.
Although improvements in endothelium-dependent microvas-
cular reactivity have been observed after acute flavanone sup-
plement and orange juice intake (13), currently no data support
the acute effect of dietary flavanones on central arterial stiffness,
cardiac autonomic regulation, or platelet reactivity.
A growing number of bioavailability studies have established
the pharmacokinetic characteristics of a range of flavanone
metabolites (i.e., phase II conjugates of the parent structure)
after orange juice intake (14–16), with data suggesting that the
phenolic metabolites contribute substantially to flavanone bio-
availability (17, 18). However, few studies have examined the
potential importance of orange juice–derived flavanone and
phenolic metabolites on cardiovascular function. Studies in-
vestigating similar phenolic metabolites derived from olive oil
or blueberries have, however, reported acute effects on cardio-
vascular risk biomarkers (19, 20).
We therefore conducted a 3-arm, acute, randomized, placebo-
controlled crossover trial in men at moderate CVD risk, in whom
endothelial function, a range of cardiovascular risk biomarkers,
and plasma flavanone metabolites were assessed 5 h after in-
gestion of a single dose of orange juice, a hesperidin- and vitamin
C–matched supplement, or a matched control.
METHODS
Study population
Sixteen healthy men aged 51–69 y, who were nonsmokers but
with a 10–20% risk of CVD in the following 10 y [estimated by
using the British Hypertension Society absolute risk calculator
(21)] at screening, were recruited and enrolled by the research
team (comprising research scientists and research nurses). In-
eligibility criteria were past or existing diabetes; cancer or he-
patic, renal, digestive, hematologic, neurologic, or thyroidal
diseases; a resting blood pressure .160/95 mm Hg at screening;
or use of lipid-lowering, antihypertensive, or vasoactive medi-
cation. In addition, antibiotic or flu vaccination (within 3 mo
before and during the study) was precluded, given the impact of
antibiotics on microflora and flavanone bioavailability (22), as
was intake of flavonoid-containing supplements (for $1 mo
before and throughout the study). Clinical guidance was sought
when changes in health were reported, and continued eligibility
to participate was monitored. The study was approved by the
local ethics committee; followed the principles of the Declara-
tion of Helsinki; was conducted at the Clinical Research and
Trials Unit, University of East Anglia (United Kingdom) be-
tween April 2012 and May 2013; and was registered at clin-
icaltrials.gov as NCT01530893. All participants provided written
informed consent before study commencement.
Study design
Before identical experimental periods ($1 wk apart), partic-
ipants followed a diet low in flavonoids (for 72 h); refrained
from strenuous exercise (for 48 h); avoided alcohol, caffeine,
and nitrate/nitrite-containing foods (for 24 h); and drank only
commercially available bottled water low in potentially vaso-
active nitrate/nitrite (Buxton Water) (for 24 h). The night before
each experimental period, participants consumed a standardized
low-flavonoid meal (,1 mg estimated flavonoid content) before
observing an overnight fast (with only bottled water consumed
for$10 h). Compliance to the diet and lifestyle restrictions were
assessed at interview, and adherence to the dietary restrictions
was determined via a 24 h-dietary recall. Food intake data were
assessed by using a standardized food intake database (WISP
V4.0; Tinuviel Software).
Experimental periods were conducted in a quiet, light-
subdued, and temperature-ambient (22–248C) room with
cardiovascular measures performed on the same body side on
each occasion in a supine position at rest ($15 min) and fol-
lowing standardized procedures. Three blood pressure assess-
ments were made by using a validated monitor (Omron 705IT;
Omron Health Care Co.). Cardiac baroreflex sensitivity (a
measure of cardiac autonomic function) was assessed from
12 min of continuous middle-finger arterial pressure data (by
using a Portapres device operated by Beatscope 1.1. software
with hand-to-heart height adjustment; TNO Biomedical In-
strumentation) and analyzed by the sequential cross-correlation
method (23). Reactive hyperemia-peripheral arterial tonometry
(RH-PAT), a measure of endothelial function in the micro-
vasculature of the finger, was assessed by using EndoPAT
equipment (Itamar Medical) as previously described (24).
Carotid-to-femoral pulse wave velocity and central augmen-
tation index assessment (normalized for heart rate at 75 beats/
min), measures of central arterial stiffness, were assessed by
using Vicorder equipment (Skidmore Medical) as described
previously [(25) and (26), respectively]. The central augmen-
tation index assessment was normalized for heart rate because
of the known association between the augmentation index and
heart rate (27). Blood samples were collected at the midpoint
of the battery of cardiovascular measures on the contralateral
arm, immediately processed, and stored at 2808C. Height and
weight were measured to calculate BMI (in kg/m2).
The intervention was administered after baseline assess-
ment, and cardiovascular measures and blood collection were
repeated in an identical sequence at 5 h postintervention; 5 h
was selected to coincide with the anticipated time of maximal
flavanone plasma concentration, on the basis of previous data
(15). During the experimental period, participants consumed
low-nitrate/nitrite water ad libitum, and their diet was con-
trolled: a flavonoid-free standardized lunch (660 kcal, 31.1 g
protein, 95.6 g carbohydrate, and 26.8 g fat) was provided 1.5 h
after the intervention.
Intervention products
Before study commencement, orange juice (supplied by the
Florida Department of Citrus) and hesperidin supplement (a
kind gift from Miguel Aragu¨és, Alicante, Spain) were ana-
lyzed for hesperidin, narirutin, and vitamin C content by
using HPLC-diode array detection (14) (typical chro-
matograms are shown in Supplemental Figure 1). A dose of
320 mg hesperidin, chosen on the basis of vascular efficacy
(13) and achievable dietary intakes (6), was provided by 767 mL
orange juice (Table 1) that was sourced from a single batch
and stored at 2208C. The hesperidin supplement intervention
was matched in hesperidin content, whereas all interventions
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(i.e., orange juice, hesperidin supplement, and control) were
matched for vitamin C, sugars, and fluid volume by using
a low-nitrate/nitrite bottled water, given the potential vasoactive
properties of nitrate/nitrite-containing products (28) (Table 1).
At each experimental period, intervention drinks (orange juice
or control) were prepared by independent scientists (following
a computer-generated, random-sequence allocation, held by an
independent scientist) and served in opaque drinking vessels.
Scientists conducting the research and analyzing the data re-
mained blinded throughout the study, whereas participants were
blinded to the hesperidin supplement but not the orange juice
intervention because of unavoidable differences in taste. Fla-
vanone contents of the orange juice and hesperidin supplement
were stable over the course of the study (pre- and poststudy
CV = 5.0%).
Plasma metabolite analysis
Naringenin-7-glucuronide was purchased from Bioquote, 3-
hydroxyhippuric acid from Enamine, and hesperetin, naringenin,
and 53 phenolics from Sigma Aldrich (for the list of all phenolics,
see Supplemental Figure 2). Glucuronide or sulfate conjugates
of protocatechuic acid, vanillic acid, isovanillic acid, and ben-
zoic acid were synthesized at the University of St. Andrew
following published methods (29). After solid-phase extraction
(using Strata-X columns; Phenomenex), acidified heparinized
plasma was analyzed by HPLC (1200 Agilent series HPLC;
Agilent Technologies) coupled to an electrospray ionization
mass spectrometer (AB Sciex 3200 series Q-trap MS/MS; AB
Sciex) in scheduled multiple-reaction monitoring mode and by
using previously optimized and validated methods (30), with
modifications for the quantification of flavanone phase II me-
tabolites [based on previous findings (14, 15, 17)] and putative
phenolic phase II metabolites, of which analytic standards were
not available. A systematic screen of a pooled plasma sample
was explored for 158 potential metabolites. For a description of
the screening strategy, a typical HPLC–mass spectrometer trace
of the final method, the corresponding analytic identification
parameters, and compound structures with Biochemical
Nomenclature, see Supplemental Figure 2, Supplemental
Figure 3, Supplemental Table 1, and Supplemental Table
2, respectively.
Plasma vitamin C was analyzed by using commercial ascor-
bate assay kits (No. 7004240; Cayman Chemical).
Plasma cardiovascular risk biomarkers
Platelet reactivity was assessed by whole-blood flow cytom-
etry as previously described (31). Briefly, sodium-citrated blood
was treated with fluorophore-conjugated monoclonal anti-
bodies (i.e., CD61-allophycocyanin and CD62p-phycoerythrin
from eBioscience and PAC1-fluorescein isothiocyanate from
BD bioscience), and platelets were left unstimulated or acti-
vation was induced by addition of ADP (1 mmol/L; Alpha
Laboratories) or collagen-related peptide (0.4 mg/mL; De-
partment of Biochemistry, University of Cambridge). After a
20-min incubation in the dark at room temperature, samples
were fixed with 1% formyl saline and stored at 48C in the
dark until analysis on the same day by using a BD Accuri C6
Flow Cytometer (Becton Dickinson). Ten thousand platelet
events (i.e., events with CD61-positive fluorescence) were
collected and platelet reactivity was assessed as the per-
centage of platelets that expressed P-selectin (i.e., CD62p-
positive fluorescence) and the activated conformation of
fibrinogen-binding receptor glycoprotein IIb/IIIa (i.e., PAC1-
positive fluorescence).
NAPDH oxidase gene expression was assessed by measuring
serum soluble gp91phox (i.e., the catalytic core of NADPH oxi-
dase) by using ELISA as previously described (32). Briefly,
duplicate serum samples were assayed with anti-gp91phox (Santa
Cruz Biotechnology) coated plates, and spectrophotometric
quantification was established against standard curves (New
England Peptide).
TABLE 1
Composition of the intervention products
Intervention
Control Orange juice Hesperidin supplement
Drink volume, mL 767 767 767
Supplement Vitamin C Cellulose Hesperidin supplement and vitamin C
Sugar,1 g 68.0 68.0 68.0
Hesperidin,2 mg 0 320 320
Narirutin,2 mg 0 48 16
Vitamin C,2 mg 439 439 439
1Matched sugar composition: 16.6 g glucose, 18.0 g fructose, and 33.4 g sucrose (data provided by the Florida
Department of Citrus).
2Quantified in house by using HPLC.
TABLE 2
Characteristics of overnight fasted study participants (n = 16) at screening
Mean 6 SEM Range
Age, y 60.6 6 1.4 51–69
Absolute cardiovascular disease risk,1 % 15.8 6 0.7 10–20
BMI, kg/m2 25.6 6 0.8 22–35
Systolic blood pressure, mm Hg 136.2 6 3.0 111–155
Diastolic blood pressure, mm Hg 82.6 6 1.6 73–94
Plasma glucose, mmol/L 5.0 6 0.1 3.9–6.0
Plasma triglycerides, mmol/L 1.1 6 0.1 0.6–2.3
Plasma total cholesterol, mmol/L 5.2 6 0.1 4.2–6.5
Plasma HDL cholesterol, mmol/L 1.3 6 0.1 0.9–1.9
Plasma LDL cholesterol, mmol/L 3.4 6 0.1 2.6–4.4
1Ten-year absolute cardiovascular disease risk as calculated by using
the British Hypertension Society risk calculator (21).
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Sample size and statistical analysis
To detect a 0.35 increase in RH-PAT (our primary outcome
measure) [assuming an SD of 0.4, based on previous data (33)]
with 80% power and at the 5% significance level, we required
a sample size of 14 participants to complete the study. Differ-
ences in study endpoints between interventions were analyzed by
using a linear mixed model for crossover studies (34), with
subjects nested within intervention sequence as a random effect
and experimental period, intervention sequence, baseline values,
and intervention as fixed effects. No carryover effects were
observed, as assessed by the experimental period and intervention
interaction (P . 0.05). When the model showed a significant
intervention effect, pairwise comparisons between interventions
were performed with Tukey-Kramer adjustments. Associations
between cardiovascular risk biomarkers and plasma concentra-
tions of total flavanone or total phenolic metabolites were as-
sessed by Pearson’s correlation. Data are presented as means 6
SEMs. P values ,0.05 were considered statistically significant,
and statistical analysis was performed by using R programming
language version 3.1.1 (R Development Core Team, 2009).
RESULTS
Study participants were healthy men, with a mean age of 61 y
(range: 51–69 y) and an estimated 15.8% (range: 10–20%) ab-
solute risk of CVD in the following 10 y (Table 2). Among the
16 enrolled participants, 14 completed all arms of the study; trial
participation was discontinued by 1 participant (after 1 experi-
mental period) because of inability to meet the study time
commitments, and 1 participant withdrew after 2 experimental
periods after developing an unrelated infection (Figure 1). No
serious adverse events were reported. All participants reported
adhering to dietary and exercise restrictions, and low plasma
concentrations of flavanone metabolites at baseline confirmed
adherence to a flavanone-free diet (Figure 2A). Estimated ha-
bitual energy intakes before the study day and BMI were similar
between the intervention periods (data not shown), as were
baseline measures of cardiovascular risk biomarkers (Table 3).
Total plasma flavanone metabolite concentrations were sig-
nificantly higher 5 h after the orange juice intervention than after
control (orange juice elevation vs. control: 1.75 6 0.35 mmol/L)
(Figure 2A), with hesperidin-glucuronide, naringenin-7-O-
glucuronide, and a second hesperidin-glucuronide contributing
47%, 15%, and 14%, respectively, to the total plasma flava-
none concentration (Figure 2B). The concentration of total
phenolics was significantly higher 5 h after orange juice in-
gestion than after control (orange juice elevation vs. control:
13.27 6 2.22 mmol/L) (Figure 3A), and concentrations were
8-fold higher than the concentrations of total flavanones
quantified. The major phenolic metabolites were hippuric
acid, dihydroferulic acid, dihydroferulic acid–glucuronide,
4-hydroxyphenylacetic acid, and vanillic acid, contributing
54%, 15%, 8%, 7%, and 5%, respectively, to the total plas-
ma phenolic metabolite concentration (Figure 3B). Un-
expectedly, concentrations of plasma flavanone metabolites
were not significantly elevated 5 h after the hesperidin sup-
plement intervention compared with control (P = 0.9) (Figure
2A). Plasma vitamin C concentrations increased to a similar
extent 5 h after ingestion of all interventions (Table 3).
Across the cardiovascular risk biomarkers that were assessed
(blood pressure, endothelial function, central arterial stiffness,
cardiac autonomic function, platelet activation, and NADPH
oxidase gene expression), no significant differences were
observed between the orange juice, hesperidin supplement,
and control interventions (Table 3). Likewise, the concen-
tration of total flavanone or total phenolic metabolites at 5 h
after the orange juice intervention were not significantly
associated with cardiovascular risk biomarkers (data not
shown).FIGURE 1 Participant flowchart.
FIGURE 2 Mean 6 SEM plasma concentrations of total flavanone me-
tabolites (A) at baseline (i.e., 0 h) and 5 h after intervention in men at
moderate cardiovascular disease risk [n = 16 (control), n = 14 (orange juice),
and n = 15 (hesperidin supplement)]. Differences in study endpoints between
interventions were analyzed by using a linear mixed model for crossover
studies, with subjects nested within the intervention sequence as a random
effect and experimental period, intervention sequence, baseline values, and
intervention as fixed effects (intervention effect: P , 0.0001). Post hoc
analysis with Tukey-Kramer adjustment was performed to determine which
intervention was significantly different from control. ****P , 0.0001. Iden-
tified flavanone metabolites (B) and their proportions relative to total flava-
none metabolite plasma concentrations at 5 h after the orange juice
intervention: 1, hesperetin-glucuronide; 2, naringenin-7-glucuronide; 3,
hesperetin-glucuronide; 4, hesperetin-diglucuronide; 5, hesperetin-
diglucuronide; 6, naringenin-glucuronide; 7, hesperetin; and 8, naringenin.
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DISCUSSION
In this acute intervention study, we examined whether the
consumption of orange juice or a hesperidin supplement, matched
for vitamin C, would result in acute effects on endothelial
function and a number of previously unassessed cardiovascular
risk biomarkers, including central arterial stiffness (assessed by
central pulse wave velocity and augmentation index), cardiac
baroreflex sensitivity, platelet reactivity, and NADPH oxidase
gene expression. In addition, we explored associations between
plasma flavanone or phenolic metabolites and cardiovascular risk
biomarkers.
We observed no acute change in cardiovascular risk bio-
markers, including endothelial function, 5 h after orange juice or
hesperidin consumption (Table 3). These findings therefore do
not support the previously reported acute benefits of orange juice
or flavanone supplementation on peripheral microvascular re-
activity (13). However, this study differed significantly in the
methods used to assess microvascular reactivity, times of end-
point analysis, and, notably, the design of control arms. Spe-
cifically, in the present study, vitamin C was controlled across all
interventions (including control), whereas in the study byMorand
et al. (13), vitamin C was not present in the flavanone and control
intervention arms. Indeed, in the present study, there was a ten-
dency toward favorable changes in a number of vascular function
markers (including diastolic blood pressure, endothelial function,
and central augmentation index; Table 3) in all groups (including
the vitamin C–matched control). This observation suggests that
vitamin C may be an important contributor to the bioactivity of
orange juice. It has also been shown that measurements of
vascular reactivity vary between different assessment methods
(35), likely because of differences in the vascular beds being
assessed, which may further explain the differential findings
between this and previous studies of microvascular reactivity.
In the present study, we identified an extensive number of
plasma flavanone and phenolic metabolites, including 2 flava-
none aglycones, 6 flavanone-glucuronides (as previously iden-
tified) (14–16), and a range of circulating phenolic metabolites
after orange juice intake, of which 7 were previously detected
only in urine (17, 18) and 8 previously unidentified (Figures 2B
and 3B). Total plasma flavanone conjugate concentration (Fig-
ure 2A) reflected those previously reported in the literature (i.e.,
0.2–1.6 mmol/L) (14, 15, 17), whereas total phenolic metabolite
concentrations (Figure 3A) were observed at concentrations
8-fold higher than those of the flavanone metabolites (Figure 2A).
This finding is further supported by studies that reported the
recovery of 37–88% of ingested flavanones as phenolic metab-
olites in 24-h urine after intake of orange juice (17, 18). In the
present study, we also report previously unidentified phenolic
metabolites, again highlighting the complexity of flavanone
metabolism. Overall, these data indicate that after flavanone
consumption, the major circulating metabolites are phenolic
breakdown products derived from the flavonoid backbone.
Although our data did not support correlations between car-
diovascular biomarkers and the concentration of flavanone or
phenolic metabolites, plasma hesperetin metabolites (phase II
metabolites of the parent structure) have been associated with
beneficial effects on endothelial function after acute flavanone
intake in previous studies (r = 0.70, P = 0.0001) (13). Our data
have shown that phenolic metabolites of flavanones are abundant
in plasma within 5 h of orange juice intake, and these metabo-
lites should remain a focus of future research exploring their
contribution to the vascular effects of orange juice. Interestingly,
the collective plasma concentration of the 23 metabolites was
comparable to the observed increase in concentrations of plasma
vitamin C (Table 3), suggesting that they collectively reach
concentrations of potential biological significance (i.e., 15.20 6
2.15 mmol/L). In contrast to the orange juice intervention, there
were minimal flavanone and phenolic metabolites identified 5 h
after intake of the hesperidin supplement. Interestingly, the
bioavailability of another flavonoid, quercetin, and its mono-
methylated derivatives (isorhamnetin and tamarixetin) also has
been shown to differ substantially depending on the dietary
source. Plasma concentrations were 3.5–9 times lower when
quercetin was consumed as a supplement than with a matched
intake within a food matrix (36).
A number of limitations of the present study are worth noting.
Although cardiovascular risk biomarkers were assessed at 5 h
after intake, which is the anticipated peak flavanone plasma
concentration [based on previous flavanone pharmacokinetic data
(15)], it remains possible that beneficial cardiovascular effects
could have been observed after a more prolonged (5–24 h or
several weeks/mo) exposure. In addition, the present study used
the RH-PAT index to measure fingertip endothelial function, and
although flow-mediated dilatation of the brachial artery is gen-
erally accepted as a more sensitive method of assessing endo-
thelial function (37) and CVD risk (38), an improvement in the
RH-PAT index has recently been observed after an acute flavo-
noid intervention (39).
FIGURE 3 Mean 6 SEM plasma concentrations of total phenolic me-
tabolites (A) at baseline (i.e., 0 h) and 5 h after the control (n = 16) and
orange juice (n = 14) intervention in men at moderate cardiovascular disease
risk. Differences in study endpoints between interventions were analyzed by
using a linear mixed model for crossover studies, with subjects nested within
intervention sequence as a random effect and experimental period, interven-
tion sequence, baseline values, and intervention as fixed effects (intervention
effect: ****P , 0.0001). Identified phenolic metabolites (B) and their pro-
portions relative to total phenolic metabolite plasma concentrations at 5 h
after the orange juice intervention: 1, hippuric acid; 2, dihydroferulic acid; 3,
dihydroferulic acid–3-glucuronide; 4, 4-hydroxyphenylacetic acid; 5, vanil-
lic acid; 6, hydroxyhippuric acid; 7, iso/ferulic acid–glucuronide; 8, 3-
hydroxyhippuric acid; 9, isovanillic acid; 10, 3-hydroxyphenylacetic acid; 11,
vanillic acid–glucuronide; 12, isovanillic acid–glucuronide; 13, iso/vanillic
acid–glucuronide; 14, 4-hydroxy-benzoic acid; and 15, benzoic acid–4-
glucuronide.
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In conclusion, we detected relatively high (micromolar)
concentrations of 23 plasma flavanone and phenolic metabolites
5 h after orange juice intake but observed no acute changes in
simultaneously assessed cardiovascular risk biomarkers, relative
to a sugar and vitamin C–matched control. It is clear that the
acute effects of flavanone consumption remain in question, and
further evidence is required to establish the exact contribution of
flavanones in comparison with other potential bioactives in cit-
rus fruit (including vitamin C), the effect of the food matrix, the
contribution of flavanone-derived phenolic metabolites, and,
ultimately, the cardiovascular response to longer-term flavanone
and phenolic metabolite exposure.
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